Wim Schuermans has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nationwide Harmonization Effort for Semi-Quantitative Reporting of SARS-CoV-2 PCR Test Results in Belgium

    by Lize Cuypers, Jannes Bode, Kurt Beuselinck, Lies Laenen, Klaas Dewaele, Reile Janssen, Arnaud Capron, Yves Lafort, Henry Paridaens, Bertrand Bearzatto, et al.

    From early 2020, a high demand for SARS-CoV-2 tests was driven by several testing indications, including asymptomatic cases, resulting in the massive roll-out of PCR assays to combat the pandemic. Considering the dynamic of viral shedding during the course of infection, the demand to report cycle threshold (Ct) values rapidly emerged. As Ct values can be affected by a number of factors, we considered that harmonization of semi-quantitative PCR results across laboratories would avoid potential divergent interpretations, particularly in the absence of clinical or serological information. A proposal to harmonize reporting of test results was drafted by the National Reference Centre (NRC) UZ/KU Leuven, distinguishing four categories of positivity based on RNA copies/mL. Pre-quantified control material was shipped to 124 laboratories with instructions to setup a standard curve to define thresholds per assay. For each assay, the mean Ct value and corresponding standard deviation was calculated per target gene, for the three concentrations (107, 105 and 103 copies/mL) that determine the classification. The results of 17 assays are summarized. This harmonization effort allowed to ensure that all Belgian laboratories would report positive PCR results in the same semi-quantitative manner to clinicians and to the national database which feeds contact tracing interventions.


  • Molecular Identification of Cutaneous Alternariosis in a Renal Transplant Patient

    by W. Schuermans, K. Hoet, L. Stessens, J. Meeuwissen, A. Vandepitte, A. Van Mieghem, K. Vandebroek, E. Oris, G. Coppens

    Cutaneous alternariosis is a rare condition, caused by an uncommon opportunistic pathogen. The most frequently affected individuals are immunosuppressed patients, e.g., organ transplant patients on immunosuppressive therapy. Clinical manifestations range from local skin lesions to disseminated disease. We present a case report of cutaneous alternariosis in a renal transplant recipient, confirmed by histological examination and molecular means. In addition, a review of the literature was performed.


  • Open Access

    Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form

    by Wim Schuermans, Hans Orlent, Isabelle Desombere, Patrick Descheemaeker, Hans Van Vlierberghe, Anja Geerts, Xavier Verhelst, Marijke Reynders, Elizaveta Padalko

    As different hepatitis C virus (HCV) genotypes respond differently to initiated therapy, correct HCV genotyping is essential. A potential risk for misclassification of the intergenotypic HCV circulating recombinant form (CRF) 2k/1b strains exists, depending on the genotyping method used. The aim was to investigate the differences in HCV genotyping methods with regard to CRF 2k/1b and to gain insight in the prevalence of the CRF 2k/1b. Genotyping results by Versant HCV Genotype Assay were compared with nonstructural protein 5B (NS5B) sequencing. In total, from November 2001 until March 2015, 3296 serum samples were analyzed by Versant HCV Genotype Assay. As misclassified CRF is harbored among HCV genotype 2, we further focused our search on 142 (4.3%) samples positive for HCV genotype 2. On 116 (81.7%) retrieved samples, the NS5B sequencing was performed. Twelve out of the 116 retrieved samples (10.3%) were classified as CRF 2k/1b by sequencing of the NS5B region. Ten of these 12 samples were originally misclassified as genotype 2a or 2c, while 2 of them were misclassified as genotype 2. Our results show that the current prevalence of CRF 2k/1b is underestimated. The importance of correct HCV genotyping is emphasized, considering the tailored choice of treatment regimen and overall prognosis.


  • Comments on the impact of genotyping method on the subtype distribution of HCV genotype 1

    by C. Van Den Borre, W. Schuermans, H. Van Vlierberghe, A. Geerts, X. Verhelst, E. Padalko

    • 1 September 2014
      • Vol. 77  (3) , 359-61

    Let's not forget herpes simplex virus in case of fulminant hepatic failure.

    by W Schuermans, S Mulliez, E Padalko, M Reynders, A Boel, K Van Vaerenbergh, H De Beenhouwer

    Fulminant herpes simplex virus (HSV) hepatitis is a rare condition, which is usually identified only after orthotopic liver transplantation (OLT) or at autopsy. The most commonly affected individuals are immunosuppressed patients, although HSV hepatitis can occur in immunocompetent patients as well. A high degree of suspicion combined with early diagnostic modalities may improve survival. We present a case report of fulminant herpetic hepatitis, requiring OLT. In addition, a review of the literature was performed.


  • The order of draw: much ado about nothing?

    by C. Indevuyst, W. Schuermans, E. Bailleul, P. Meeus

    Summary: Introduction: The ‘order of draw’ has been advocated since 1982 to reduce the risk of cross‐contaminating blood tubes with additives from a previously filled tube.Methods: We studied 193 patients receiving oral anticoagulation. Multiple tubes were collected in a specific order using the Sarstedt Safety Monovette System. We evaluated the effect of the ‘order of draw’ on the prothrombin time/international normalized ratio (PT/INR) and the activated partial thromboplastin time (APTT) when the citrate tube is drawn as the first tube, second tube or after a heparin, EDTA or serum tube with clot activator.Results: There was no statistically significant influence on the PT/INR. The same applies for the APTT measured on a citrate tube drawn after a heparin tube. There was a small, but statistically significant bias on the APTT when the citrate tube was drawn as the first tube, after an EDTA tube or after a serum tube with clot activator. We consider this bias (max. 0.2 s) as not clinically significant.Conclusion: The order of draw has no significant influence on the PT/INR and APTT when measured on a Sarstedt citrate tube filled without the use of a discard tube or after a heparin, EDTA or serum tube with clot activator.